EUVIMEDOdkrijte EUVIMED
CrossrefInformačná karta

MITF maintains genome stability in nonmelanocyte lineages

Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson

Molecular Oncology · 2026-11 · 20 (11) · 2839-2859

DOI: 10.1002/1878-0261.70273 ↗
AbstraktBibliografické údaje

Abstrakt

Microphthalmia‐associated transcription factor (MITF) is crucial for development and survival of melanocytes and serves as a lineage‐specific oncogene that is amplified in 10–20% of melanomas. The role of MITF in pathways maintaining genome integrity, such as DNA replication, DNA repair, and mitosis has been extensively studied in melanocytes. In addition to its pro‐survival role in melanoma, recent studies have shown that MITF expression has important implications for cancer progression and treatment in other cancer types. Nevertheless, studies on the role of MITF in other tissues are scarce. Here, we show that depletion of MITF causes genome instability in nonmelanocytic cell lineages, which results in activation of P53, cell cycle arrest, and apoptosis. Moreover, we show that P53 activation in MITF‐depleted cells is dependent on LATS2, a kinase with an established role in the Hippo pathway. Finally, we show that LATS2 mediated upregulation of P53 is ATR‐dependent. Collectively, this study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage, which might contribute to the tumor suppressive function of MITF.

Vedomosti, ktoré zodpovedajú vašej práci.

Od bezplatného začiatku cez osobnú rešerš literatúry až po kompletný Research Suite.

Zobraziť tarify →

Sú zahrnuté všetky plné texty vydavateľov?

Nie. Bibliografické záznamy, abstrakty a plné texty sú odlišné typy obsahu. To, či je plný text dostupný, závisí od zdroja, Open Access a vašich existujúcich licencií. Tarif EUVIMED nenahrádza dodatočné práva vydavateľa.

Zobraziť tarify →